News Releases
Sep 12, 2023
Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery
Additional Formats
Sep 06, 2023
Lyra Therapeutics to Participate in Upcoming Investor Conferences
Additional Formats
Aug 29, 2023
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
Additional Formats
Aug 08, 2023
Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Additional Formats
Jul 13, 2023
Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference
Additional Formats
Jun 02, 2023
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Additional Formats
Jun 02, 2023
Lyra Therapeutics to Present at Jefferies Healthcare Conference
Additional Formats
Jun 01, 2023
Lyra Therapeutics Announces Closing of $50.0 Million Private Placement
Additional Formats
May 26, 2023
Lyra Therapeutics Announces $50.0 Million Private Placement
Additional Formats
May 12, 2023
Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Additional Formats
Displaying 1 - 10 of 16